KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Inventory (2016 - 2026)

Pacira BioSciences has reported Inventory over the past 17 years, most recently at $150.4 million for Q1 2026.

  • For Q1 2026, Inventory rose 12.42% year-over-year to $150.4 million; the TTM value through Mar 2026 reached $150.4 million, up 12.42%, while the annual FY2025 figure was $152.9 million, 22.02% up from the prior year.
  • Inventory for Q1 2026 was $150.4 million at Pacira BioSciences, down from $152.9 million in the prior quarter.
  • Over five years, Inventory peaked at $157.7 million in Q3 2025 and troughed at $92.1 million in Q2 2023.
  • A 5-year average of $115.5 million and a median of $103.7 million in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 60.45% in 2022 and later decreased 10.31% in 2023.
  • Year by year, Inventory stood at $96.1 million in 2022, then increased by 8.63% to $104.4 million in 2023, then grew by 20.06% to $125.3 million in 2024, then rose by 22.02% to $152.9 million in 2025, then decreased by 1.63% to $150.4 million in 2026.
  • Business Quant data shows Inventory for PCRX at $150.4 million in Q1 2026, $152.9 million in Q4 2025, and $157.7 million in Q3 2025.